Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer

ER positive (ER+) and HER2 negative (HER2-) breast cancers are routinely treated based on estrogen dependence. CDK4/6 inhibitors in combination with endocrine therapy have significantly improved the progression-free survival of patients with ER+/HER2- metastatic breast cancer. Gene expression profil...

Descripción completa

Detalles Bibliográficos
Autores principales: Knudsen, Erik S., Witkiewicz, Agnieszka K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342463/
https://www.ncbi.nlm.nih.gov/pubmed/27564114
http://dx.doi.org/10.18632/oncotarget.11588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342463/
https://www.ncbi.nlm.nih.gov/pubmed/27564114
http://dx.doi.org/10.18632/oncotarget.11588

Ejemplares similares